Angiogenesis
Affitech-Identified Fully Human Anti-VEGF Antibody Candidate is as Effective as Avastin(R) in Preclinical Cancer Models
Published in Oncology Business Week, December 9th, 2007
Affitech AS, the human antibody therapeutics company announced that its partner, Peregrine Pharmaceuticals, has reported that its anti-VEGF antibody R84, an antibody identified by Affitech, selectively blocks the interaction of vascular endothelial growth factor (VEGF) to VEGF receptor 2 (VEGFR2); and is as effective as Avastin(R) (bevacizumab) in inhibiting growth of established tumors in a preclinical breast cancer model. Results were presented at IBC's 5th Annual International Anti-Angiogenesis Conference in Boston on November 12, 2007.
R84 selectively blocks VEGF binding only to VEGFR2, the receptor primarily responsible for tumor angiogenesis, unlike Avastin(R) and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- Adenocarcinoma
Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas - America's Health Insurance Plans
HSA Plans are Covering Preventive Care on a First-Dollar Basis - American Airlines, Inc.
American Airlines Invites the Public to Join Marlo Thomas and St. Jude Patients to Create One-of-a-Kind Mural to Celebrate 80 Years of Service in the Greater New York Area - American Red Cross, Southeastern Michigan Blood Services Region
Help Save Lives This Holiday Season by Donating Blood - AngioDynamics, Inc.
AngioDynamics to Present at 19th Annual Piper Jaffray Health Care Conference - Angiogenesis
Research Uncovers Molecular Function of Endosialin Target of MORAb-004, Anti-Angiogenic Antibody Being Evaluated for Cancer, Neovascular Disease - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
